Laboratory Animal Facility

Ethical, scientific, and regulatory-compliant preclinical research — generating safety, pharmacology, and toxicology data prior to transition into clinical research.

Compliance: GLP HADYEK EU Directive 2010/63/EU 3R Principles ISO/IEC 17025

Introduction & Scope

The Laboratory Animal Facility operating within the Omega CRO and HelixLab ecosystem provides the ethical, scientific, and regulatory-compliant housing, monitoring, and inclusion of laboratory animals used in preclinical research.

This infrastructure is designed to support the generation of safety, pharmacology, and toxicology data prior to transition into clinical research. Laboratory, analytical, and operational services are delivered through Omega's internal units or authorized partner infrastructures complying with applicable standards.

Regulatory & Ethical Framework

All activities involving laboratory animals are conducted in full compliance with national and international ethical and regulatory requirements. Animal welfare and scientific integrity are addressed in parallel.

HADYEK Approval

Approval by the Local Ethics Committee for Animal Experiments. All study protocols undergo ethical review before initiation.

3R Principles

Replacement, Reduction, and Refinement — minimizing animal use while maximizing scientific output and welfare.

EU Directive 2010/63/EU

Full alignment with European Union Directive on the protection of animals used for scientific purposes.

GLP Principles

Adherence to Good Laboratory Practice principles for reliability, integrity, and quality of preclinical safety data.

Animal Species & Housing Infrastructure

  • Small laboratory animals, primarily guinea pigs
  • Species- and age-appropriate caging and environmental enrichment
  • Controlled temperature, humidity, and lighting conditions
  • Biosafety measures and cross-contamination prevention

Animal Welfare & Daily Monitoring

  • Daily clinical observation and health checks
  • Body weight monitoring and general condition assessment
  • Early detection of stress and pain indicators
  • Veterinary supervision and intervention protocols

Experimental Applications & Procedures

Conducted by qualified personnel in accordance with approved protocols. Scientific data quality maintained while minimizing animal burden.

Dose administration (oral, parenteral)
Blood & biological sample collection
Behavioral & physiological observations
Anesthesia & analgesia applications

Safety, Toxicology & Pharmacology

Generation of safety and toxicology data prior to transition into clinical research.

Acute & subchronic toxicity
Dose-response & tolerability
Target organ toxicity observations
Preliminary PK/PD evaluations

Sample Management & Analytical Integration

Biological samples obtained from laboratory animals are processed and analyzed in an integrated manner with the HelixLab central laboratory infrastructure.

Traceable Collection

Blood, tissue, and biological samples with chain-of-custody approach.

HelixLab Integration

Biochemistry, hematology, and histopathology analyses on centralized platform.

Biorepository Storage

Long-term storage of animal-derived biological samples for reanalysis.

Preclinical to Clinical Continuum

Continuity between preclinical and clinical research phases is critical for scientific accuracy, patient safety, and operational efficiency. The Omega CRO ecosystem addresses this through an integrated and traceable framework.

Preclinical Phase: Laboratory Animals & Translational Preparation

Studies establish the scientific foundation for transition into clinical phases with respect to safety, tolerability, pharmacology, and toxicology.

Dose-response relationship evaluation
Target organ toxicity monitoring
Biomarker candidate identification

Translational Bridge: Sample, Data & Interpretive Continuity

Samples evaluated in an integrated manner with HelixLab, enhancing comparability between animal models and clinical samples.

Preclinical biomarkers → clinical phases
Data-driven rational dose selection
Reduced uncertainty in First-in-Human

Clinical Phase: Safety & Central Laboratory Continuity

With transition into the clinical phase, Safety Lab and central laboratory infrastructures ensure participant safety and longitudinal evaluation.

Hematological & biochemical safety monitoring
Reduced site-to-site variability (central lab)
Early detection of preclinical risks

Strategic Contribution & Decision Quality

Reduced Failure Risk

Reduction of failure risk in clinical phases through stronger preclinical foundation.

No Unnecessary Repeats

Avoidance of unnecessary repeat studies through integrated, traceable data transfer.

Predictable Development

A more predictable and manageable clinical development process.

Planning Preclinical Studies?

Discuss your preclinical-to-clinical transition plan with our integrated team.

Request a Consultation